Recent Updates
Recently added Catalysts
VRAX Positive Sentiment

Virax Biolabs Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September

Tuesday, August 26, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Virax Biolabs has partnered with Emory University to conduct clinical studies on ViraxImmune™, targeting immune profiling in individuals with post-viral syndromes, particularly long COVID. This collaboration aims to advance diagnostics and improve patient outcomes. The company is also preparing for an FDA pre-submission meeting scheduled for early September.
Price reaction · baseline $19.35 (2025-08-25 close) · hit pre-market · 1 other VRAX headline(s) in the window, move may be shared
day 0 close
-18.2%
day 1 · peak
-23.2%
day 3
-21.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Partnership with Emory University enhances research credibility.
  • Focus on post-viral syndromes addresses a significant health issue.
  • Preparation for FDA pre-submission meeting indicates progress.

Full Press Release Details

• News
• August 26, 2025
LONDON , Aug. 26, 2025 /PRNewswire/ — Virax Biolabs Group Limited (NASDAQ: VRAX) (“Virax” or the “Company”), an innovative biotechnology company focused on immune response detection and diagnostics, today announced it has signed a Research Services Agreement (“RSA”) with Emory University’s Center for the Advancement of Diagnostics for a Just Society (“ADJUST Center”) to conduct clinical studies of ViraxImmune™. These studies will focus on immune profiling in individuals with post-viral syndromes, beginning with post-acute sequelae of SARS-CoV-2 (“PASC”), commonly known as long COVID…

Frequently Asked Questions

What is the focus of the ViraxImmune™ clinical studies?

The studies focus on immune profiling in individuals with post-viral syndromes, starting with long COVID.

Who is partnering with Virax Biolabs for the studies?

Virax Biolabs has partnered with Emory University's ADJUST Center for the clinical studies.

When is the FDA pre-submission meeting scheduled?

The FDA pre-submission meeting is scheduled for early September.

What is the significance of the partnership with Emory University?

The partnership enhances research credibility and aims to improve diagnostics for post-viral syndromes.

ShareAdd on Google
Tags: VRAX Virax Biolabs Emory University long COVID FDA pre-submission immune profiling
Last updated: Aug 26, 2025